Moderna wins patent lawsuit against BioNTech/Pfizer
Pfizer convinces US Patent Office to cancel two Moderna COVID-19 vaccine patents
Pfizer and BioNTech won a round in their legal battle with Moderna over COVID-19 vaccine patents on Wednesday, convincing a U.S. Patent Office tribunal that two patents Moderna accused them of infringing were invalid.
Moderna Inc. expects to launch a personalized cancer vaccine that it’s developing with Merck & Co. by 2027, one of its top ...
Shares of the American pharmaceutical company Moderna (MRNA) climbed over 8% in pre-market trading following strategic ...
Moderna, Inc. (NASDAQ:MRNA) shares rose for a second day on Wednesday, adding 15.94 percent to finish at $35.21 apiece as ...
CEO Stephane Bancel has bought stock for the first time on the open market since he was named the top executive in October ...
Moderna (MRNA) stock in focus as the company aims a 2027 marketing nod for Merck (MRK) partnered skin cancer vaccine. Read ...
Arbutus Biopharma and Genevant Sciences are broadening the scope of their patent infringement claims against Moderna with ...
For now, Moderna may be a good stock to put on a watch list, but it's likely too risky and volatile for the vast majority of ...
Moderna, Inc. ( NASDAQ: MRNA) TD Cowen 45th Annual Health Care Conference March 5, 2025 9:10 AM ET All right, well, good morning, everyone. Tyler Van Buren here, Senior Biotech Analyst at TD Cowen.
Moderna’s respiratory syncytial virus (RSV) vaccine mRESVIA has been approved by the Medicines and Healthcare products ...
The Trump administration confirmed it is reevaluating a $590 million human bird flu vaccine contract awarded to Moderna in ...
Madison Mills examines the trending headlines Wall Street investors need to know on today's Market Minute. Moderna (MRNA) shares pop after a German court ruled that Pfizer (PFE) and BioNTech (BNTX) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback